6-(4-氟苯基)吲哚 | 147621-16-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 6-(4-氟苯基)吲哚
• 英文名称: 6-(4-fluorophenyl)-1H-indole
• 英文别名: 6-(4-fluorophenyl)indole
• CAS: 147621-16-7
• 化学式: C₁₄H₁₀FN
• 分子量: 211.239
• InChiKey: RUYZRLREVCHREA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  15.8
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6-(4-氟苯基)吲哚 在 吡啶 、 氢氧化钾 作用下， 以 1,4-二氧六环 为溶剂， 反应 5.25h， 生成 3-(2-Chloro-acetyl)-6-(4-fluoro-phenyl)-indole-1-carboxylic acid dimethylamide
  参考文献：
  名称：

  Discovery and Evaluation of a Series of 3-Acylindole Imidazopyridine Platelet-Activating Factor Antagonists

  摘要：

  Studies conducted with the goal of discovering a second-generation platelet-activating factor (PAF) antagonist have identified a novel class of potent and orally active antagonists which have high aqueous solubility and long duration of action in animal models. The compounds arose from the combination of the lipophilic indole portion of Abbott's first-generation PAF antagonist ABT-299 (2) with the methylimidazopyridine heterocycle moiety of British Biotechnology's BB-882 (1) and possess the positive attributes of both of these clinical candidates. Structure-activity relationship (SAR) studies indicated that modification of the indole and benzoyl spacer of lead compound 7b gave analogues that were more potent, longer-lived, and bioavailable and resulted in the identification of 1-(N,N-dimethylcarbamoyl)-4-ethynyl-3-(3-fluoro-4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl] benzoyl}indole hydrochloride (ABT-491, 22m.HCl) which has been evaluated extensively and is currently in clinical development.

  DOI：

  10.1021/jm970389+
• 作为产物：
  描述：

  6-溴吲哚 、 4-氟苯硼酸 在 四(三苯基膦)钯 sodium carbonate 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 反应 17.0h， 以65%的产率得到6-(4-氟苯基)吲哚
  参考文献：
  名称：

  CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS

  摘要：

  具有化学式(I)的化合物，以及其对映体、非对映异构体、药用可接受的盐，可用作激酶调节剂，包括Btk调节。

  公开号：

  US20100160303A1

文献信息

• Platelet activating factor antagonists: imidazopyridine indoles
  申请人：Abbott Laboratories

  公开号：US05486525A1

  公开（公告）日：1996-01-23

  The present invention relates to compounds of formula ##STR1## and the pharmaceutically acceptable salts thereof which are potent antagonists of PAF and are useful in the treatment of PAF-related disorders including asthma, shock, respiratory distress syndrome, acute inflammation, transplanted organ rejection, gastrointestinal ulceration, allergic skin diseases, delayed cellular immunity, parturition, fetal lung maturation, and cellular differentiation.

  本发明涉及具有公式##STR1##的化合物及其药用可接受的盐，这些化合物是PAF的强效拮抗剂，可用于治疗与PAF相关的疾病，包括哮喘、休克、呼吸窘迫综合征、急性炎症、移植器官排斥、胃肠道溃疡、过敏性皮肤病、迟发性细胞免疫、分娩、胎儿肺成熟和细胞分化。
• Platelet activating factor antagonists
  申请人：Abbott Laboratories

  公开号：US05459152A1

  公开（公告）日：1995-10-17

  Indole compounds substituted at the 3-position by a 7-carbonyl(pyridin-3-yl)pyrrolo[1,2-c]thiazole, 7-carbonyl(pyridin-3-yl)pyrrolo[1,2-c]oxazole, or 7-carbonyl(pyridin-3-yl)pyrrolo[1,2-c]pyrrole group are potent antagionists of PAF and are useful in the treatment of PAF-related disorders including asthma, shock, respiratory distress syndrome, acute inflammation, transplanted organ rejection, gastrointesinal ulceration, allergic skin diseases, delayed cellular immunity, parturition, fetal lung maturation, and cellular differentiation.

  3位被7-羰基(吡啶-3-基)吡咯[1,2-c]噻唑、7-羰基(吡啶-3-基)吡咯[1,2-c]恶唑或7-羰基(吡啶-3-基)吡咯[1,2-c]吡咯基团取代的吲哚化合物是PAF的强效拮抗剂，可用于治疗与PAF相关的疾病，包括哮喘、休克、呼吸窘迫综合征、急性炎症、移植器官排斥、胃肠道溃疡、过敏性皮肤病、迟发型细胞免疫、分娩、胎儿肺成熟和细胞分化。
• CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS
  申请人：Liu Qingjie

  公开号：US20100160303A1

  公开（公告）日：2010-06-24

  Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, are useful as kinase modulators, including Btk modulation.

  具有化学式(I)的化合物，以及其对映体、非对映异构体、药用可接受的盐，可用作激酶调节剂，包括Btk调节。
• Agents and methods for the treatment of proliferative diseases
  申请人：——

  公开号：US20030229026A1

  公开（公告）日：2003-12-11

  The present invention provides selective kinase inhibitors of formula (I). 1

  这项发明提供了式（I）的选择性激酶抑制剂。
• The Use of Lewis Acid in the Reaction of Zinc Salts of Indoles and Acyl Chloride
  作者：ChengXi Yang、Hemantkumar H. Patel、Yi-Yin Ku、Rajendra Shah、David Sawick

  DOI：10.1080/00397919708006820

  日期：1997.6

  Abstract 3-Acylindoles have been prepared in 62 – 92% isolated yield from the corresponding indoles and acyl chlorides in the presence of AlCl3.

  摘要 在 AlCl3 存在下，已从相应的吲哚和酰氯中以 62-92% 的分离产率制备了 3-酰基吲哚。